Pharmaceuticals News

WATERTOWN, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation...

– Total revenue of $83.3 million in 3Q26, an 82% year-over-year increase – – Revuforj® (revumenib) net revenue of $60.7 million in 3Q26, a 90% y/y increase, underscores leadership in R/R NPM1m and...

– CASGEVY® revenue of $99 million in the third quarter of 2026, up 30% quarter-over-quarter and nearly six times the third quarter of 2025 – – CASGEVY approved in the U.K. for children 5 years of age...

SOUTH SAN FRANCISCO, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver...

WAYNE, Pa., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for...

NeOnc Technologies Holdings (NASDAQ: NTHI) is developing a meaningful brain cancer and blood-brain barrier story

Please read the announcement in PDF Attachment 2026_26_Share_buyback ...

Merger positions Supernus as a leading diversified central nervous system (CNS) biopharmaceutical company with a broad portfolio of marketed medicines, enhanced financial flexibility and a...

CEO Roger M. Perlmutter, M.D., Ph.D., to participate in Guggenheim 3rd Annual Healthcare Innovation Conference Fireside Chat and JP Morgan Biotech Call seriesCMO Roy Baynes, M.D., Ph.D., to...

CARSON CITY, Nev., Nov. 02, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and...